Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 51 Small Cell Lung Carcinoma 23 Breast Neoplasms 18 Sarcoma 17 Lung Neoplasms 10 Carcinoma, Hepatocellular 10 Esophageal Squamous Cell Carcinoma 9 Stomach Neoplasms 8 Neoplasms 8 Triple Negative Breast Neoplasms 7 Ovarian Neoplasms 7 Nasopharyngeal Carcinoma 7 Thyroid Neoplasms 6 Neoplasm Metastasis 6 Esophageal Neoplasms 6 Pancreatic Neoplasms 5 NSCLC 5 Colorectal Neoplasms 5 Carcinoma 5 Uterine Cervical Neoplasms 4 Pheochromocytoma 4 Endometrial Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Ovarian Epithelial 4 Recurrence 3 Paraganglioma 3 Non-squamous Non-small Cell Lung Cancer 3 Glioma 3 Fallopian Tube Neoplasms 3 Cholangiocarcinoma 3

Interventions

tremelimumab 1 durvalumab 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Malignancy × anlotinib × Clear all

NCT04216082 2020-01-02

A Study of Anlotinib in Subjects With Advanced Malignancy

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed

Advanced Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡